Key Points
- Marc Began, EVP, sold 9,278 shares on Dec. 9 at an average price of $31.21 for about $289,566, cutting his holding by 22.75% to 31,507 shares (~$983,333).
- AxoGen trades near its 1‑year high (opened $30.01; 1‑yr high $34.24) with a $1.38B market cap and broad analyst support (nine Buys, one Sell) and a consensus target of $35.56, even as the company posts negative margins and a negative PE.
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) EVP Marc Began sold 9,278 shares of the company's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $31.21, for a total value of $289,566.38. Following the sale, the executive vice president directly owned 31,507 shares of the company's stock, valued at $983,333.47. The trade was a 22.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
AxoGen Stock Performance
NASDAQ:AXGN opened at $30.01 on Thursday. The firm has a market capitalization of $1.38 billion, a PE ratio of -600.20 and a beta of 1.06. AxoGen, Inc. has a 1 year low of $9.22 and a 1 year high of $34.24. The company has a current ratio of 4.09, a quick ratio of 2.64 and a debt-to-equity ratio of 0.54. The firm's fifty day simple moving average is $22.81 and its 200 day simple moving average is $16.68.
AxoGen (NASDAQ:AXGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.03. The business had revenue of $60.08 million during the quarter, compared to analysts' expectations of $56.90 million. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%. On average, sell-side analysts anticipate that AxoGen, Inc. will post -0.29 EPS for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on AXGN shares. JMP Securities set a $34.00 target price on shares of AxoGen in a research note on Thursday, October 30th. Lake Street Capital boosted their price objective on shares of AxoGen from $30.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, December 4th. Jefferies Financial Group increased their target price on shares of AxoGen from $29.00 to $36.00 and gave the company a "buy" rating in a research note on Thursday, December 4th. Citigroup reissued a "market outperform" rating on shares of AxoGen in a research report on Thursday, October 30th. Finally, Mizuho started coverage on AxoGen in a report on Monday, December 1st. They issued an "outperform" rating and a $40.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $35.56.
Get Our Latest Stock Analysis on AxoGen
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Future Financial Wealth Managment LLC bought a new stake in shares of AxoGen in the 3rd quarter worth about $27,000. Aquatic Capital Management LLC boosted its position in AxoGen by 287.8% in the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 1,269 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in AxoGen in the third quarter valued at about $43,000. AdvisorNet Financial Inc grew its stake in AxoGen by 500.0% during the third quarter. AdvisorNet Financial Inc now owns 4,800 shares of the medical equipment provider's stock worth $86,000 after buying an additional 4,000 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of AxoGen by 189.9% during the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider's stock worth $55,000 after buying an additional 3,327 shares in the last quarter. 80.29% of the stock is owned by institutional investors.
AxoGen Company Profile
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
